Literature DB >> 18166457

Energetic effects for observed and unobserved HIV-1 reverse transcriptase mutations of residues L100, V106, and Y181 in the presence of nevirapine and efavirenz.

Marilyn B Kroeger Smith1, Lenea H Rader, Amanda M Franklin, Emily V Taylor, Katie D Smith, Richard H Smith, Julian Tirado-Rives, William L Jorgensen.   

Abstract

The effect of mutations on amino acid residues L100, V106, and Y181 for unbound HIV-1 reverse transcriptase (RT) and RT bound to nevirapine and efavirenz was investigated using Monte Carlo/free energy perturbation calculations. Using both native and bound crystal structures of RT, mutation of the amino acid residues to both those observed and unobserved in patients was carried out. The results of the calculations revealed that the variant that survives in patients dosed with either nevirapine or efavirenz had a more positive Delta Delta G value than other variants that were not observed in patients. These data suggest that the mutation observed in patients is the most effective (the one that binds the drug most weakly) of all possible codon change mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18166457      PMCID: PMC2901594          DOI: 10.1016/j.bmcl.2007.12.033

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

1.  Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity.

Authors:  M B Smith; M L Lamb; J Tirado-Rives; W L Jorgensen; C J Michejda; S K Ruby; R H Smith
Journal:  Protein Eng       Date:  2000-06

2.  Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase.

Authors:  Lee T. Bacheler
Journal:  Drug Resist Updat       Date:  1999-02       Impact factor: 18.500

3.  Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.

Authors:  D P Wang; R C Rizzo; J Tirado-Rives; W L Jorgensen
Journal:  Bioorg Med Chem Lett       Date:  2001-11-05       Impact factor: 2.823

Review 4.  New developments in anti-HIV chemotherapy.

Authors:  Erik De Clercq
Journal:  Biochim Biophys Acta       Date:  2002-07-18

5.  Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase.

Authors:  Marina Udier-Blagović; Edward K Watkins; Julian Tirado-Rives; William L Jorgensen
Journal:  Bioorg Med Chem Lett       Date:  2003-10-06       Impact factor: 2.823

6.  Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues.

Authors:  Marina Udier-Blagović; Julian Tirado-Rives; William L Jorgensen
Journal:  J Med Chem       Date:  2004-04-22       Impact factor: 7.446

Review 7.  Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases.

Authors:  Stefan G Sarafianos; Kalyan Das; Stephen H Hughes; Eddy Arnold
Journal:  Curr Opin Struct Biol       Date:  2004-12       Impact factor: 6.809

Review 8.  Molecular modeling of organic and biomolecular systems using BOSS and MCPRO.

Authors:  William L Jorgensen; Julian Tirado-Rives
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

9.  Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.

Authors:  D W Ludovici; B L De Corte; M J Kukla; H Ye; C Y Ho; M A Lichtenstein; R W Kavash; K Andries; M P de Béthune; H Azijn; R Pauwels; P J Lewi; J Heeres; L M Koymans; M R de Jonge; K J Van Aken; F F Daeyaert; K Das; E Arnold; P A Janssen
Journal:  Bioorg Med Chem Lett       Date:  2001-09-03       Impact factor: 2.823

10.  Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.

Authors:  Y Hsiou; K Das; J Ding; A D Clark; J P Kleim; M Rösner; I Winkler; G Riess; S H Hughes; E Arnold
Journal:  J Mol Biol       Date:  1998-11-27       Impact factor: 5.469

View more
  2 in total

1.  Effects of the protonation state in the interaction of an HIV-1 reverse transcriptase (RT) amino acid, Lys101, and a non nucleoside RT inhibitor, GW420867X.

Authors:  Sérgio E Galembeck; F Matthias Bickelhaupt; Célia Fonseca Guerra; Eduardo Galembeck
Journal:  J Mol Model       Date:  2014-06-26       Impact factor: 1.810

2.  Multi-Site λ-dynamics for simulated Structure-Activity Relationship studies.

Authors:  Jennifer L Knight; Charles L Brooks
Journal:  J Chem Theory Comput       Date:  2011-09-13       Impact factor: 6.006

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.